WilliamGKaelinMD
Internal Medicine • Boston, MAHematology/Oncology
Professor of Medicine, Harvard Medical School Investigator, Howard Hughes Medical Institute
Dr. Kaelin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney Street
Dana Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-3975
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1991
Johns Hopkins UniversityResidency, Internal Medicine, 1983 - 1986
Duke University HospitalResidency, Radiology-Diagnostic, 1983 - 1983
Duke University School of MedicineClass of 1982
Certifications & Licensure
MA State Medical License 1987 - 2017
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2007
- Elected Member The American Society for Clinical Investigation, 1997
- Investigator Howard Hughes Medical Institute
Publications & Presentations
PubMed
- 700 citationsRole of VHL Gene Mutation in Human CancerWilliam Y. Kim, William G. Kaelin
Journal of Clinical Oncology. 2004-12-15 - 665 citationsE2F-1 Functions in Mice to Promote Apoptosis and Suppress ProliferationSeth J. Field, Fong-Ying Tsai, Frank C. Kuo, Ana M. Zubiaga, William G. Kaelin
Cell. 1996-05-17 - 107 citationsDeubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion.Isaac S. Harris, Jennifer E. Endress, Jonathan L. Coloff, Laura M. Selfors, Samuel K. McBrayer
Cell Metabolism. 2019-05-07
Press Mentions
Resveratrol Promotes LRSAM1 E3 Ubiquitin Ligase-Dependent Degradation of Misfolded Proteins Linked with NeurodegenerationSeptember 28th, 2022- Atavistik Bio Announces $60 Million Series a Financing to Advance Genetically-Validated Targets in Metabolic Diseases and CancerAugust 24th, 2021
- Dan Hayes Witnessed Cancer History, Now He Is Documenting It in a PodcastJune 4th, 2021
- Join now to see all
Grant Support
- The Rbp2/Jarid1a/Kdm5a Histone Demethylase As A Potential Drug Target In CancerNational Cancer Institute2011–2012
- The Von Hippel-Lindau Tumor Suppressor Protein:Roles In Cancer And Oxygen SensingNational Cancer Institute2011
- P2 - Treament Of VHL-/- Clear Cell Renal Carcinoma With HIF2A SirnaNational Cancer Institute2010–2011
- Molecular Biology In Clinical Oncology WorkshopNational Cancer Institute2008–2011
- Functional Analysis Of The Von Hippel-Lindau ProteinNational Cancer Institute2006–2010
- Treament Of VHL-/- Clear Cell Renal Carcinoma With HIF2A SirnaNational Cancer Institute2009
- A Luciferase Fusion Protein Library To Identify &Monitor Ubiquitylation TargetsNational Cancer Institute2007–2008
- Signal Transduction By The Retinoblastoma ProteinNational Cancer Institute1998–2008
- 2006 Cancer Model MechanismsNational Cancer Institute2006
- Real-Time Imaging Of Hypoxia Based On VHL ActivityNational Cancer Institute2005–2006
- Using Synthetic Lethality To Select Cancer Drug TargetsNational Cancer Institute2004–2005
- Functional Analysis Of The Von Hippel Lindau ProteinNational Cancer Institute2001–2005
- Real-Time Imaging Of Hypoxia Based On VHL ActivityNational Cancer Institute2004
- Conference On Cell Cycle 2001National Cancer Institute2001
- Functional Analysis Of The Von Hippel/Lindau ProteinNational Cancer Institute1996–2000
- Retinoblastoma Susceptibility Gene--Functional AnalysisNational Cancer Institute1990–1994
- Retinoblastoma Susceptibility Gene: Functional AnalysisNational Cancer Institute1990
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
